<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950209</url>
  </required_header>
  <id_info>
    <org_study_id>2007/17</org_study_id>
    <secondary_id>2007-002791-33</secondary_id>
    <nct_id>NCT00950209</nct_id>
  </id_info>
  <brief_title>Acute Effect of Intensive Insulin Infusion on Intestinal Triglyceride-rich-lipoprotein-apoB48 Metabolism in Type 2 Diabetic Patients</brief_title>
  <official_title>Acute Effect of Intensive Insulin Infusion on Intestinal Triglyceride-rich-lipoprotein-apoB48 Metabolism in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atherosclerotic cardiovascular disease (ASCD) is the first cause of morbidity and mortality&#xD;
      at type 2 diabetes. The typical dyslipidemia that is associated with insulin resistance,&#xD;
      which includes a postprandial elevation of triglyceride-rich lipoproteins (TRLs) with excess&#xD;
      of intestinal triglyceride-rich-lipoprotein-apoB48 (TRL-apoB48), is felt to play an important&#xD;
      role in the accelerated ASCD.&#xD;
&#xD;
      The investigators' objectives in this study are to determine whether an acute elevation of&#xD;
      plasma insulin, secondarily to plasma insulin infusion, modulates the production and the&#xD;
      clearance rates of intestinal TRL-apoB48 in type 2 diabetic patients in the fed state and to&#xD;
      determine if this is a direct effect of insulin or an indirect effect due to the decrease of&#xD;
      plasma FFA or the decrease of plasma glucose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Atherosclerotic cardiovascular disease (ASCD) is the first cause of morbidity and&#xD;
      mortality at type 2 diabetes. The typical dyslipidemia that is associated with insulin&#xD;
      resistance, which includes a postprandial elevation of triglyceride-rich lipoproteins (TRLs)&#xD;
      with excess of intestinal triglyceride-rich-lipoprotein-apoB48 (TRL-apoB48), is felt to play&#xD;
      an important role in the accelerated ASCD. Recently, intestinal TRL-apoB48 overproduction&#xD;
      appeared as a newly recognized component of insulin resistance. Despite ample evidence&#xD;
      supporting the delayed clearance of intestinal TRL-apoB48, there is only a limited amount of&#xD;
      information in the literature regarding the factors modulating the production of intestinal&#xD;
      TRL-apoB48 in the setting of insulin resistance and type 2 diabetes mellitus. Several&#xD;
      arguments suggest that the intestine is not a &quot;passive&quot; organ with respect to lipoprotein&#xD;
      production, but an organ metabolically active, receiving information from intestinal lumen&#xD;
      and blood and able to modulate its syntheses and its lipid secretions according to the&#xD;
      substrata, to the insulin or to other substances. There are functional relationships between&#xD;
      the intestine and the liver. For example, it has been recently shown that acute elevation of&#xD;
      plasma free fatty acids (FFA) in humans stimulates intestinal TRL-apoB48 and hepatic&#xD;
      TRL-apoB100 production.&#xD;
&#xD;
      Aims: Our objectives in this study are to determine whether an acute elevation of plasma&#xD;
      insulin, secondarily to plasma insulin infusion, modulates the production and the clearance&#xD;
      rates of intestinal TRL-apoB48 in type 2 diabetic patients in the fed state and to determine&#xD;
      if this is a direct effect of insuline or an indirect effect due to the decrease of plasma&#xD;
      FFA or the decrease of plasma glucose.&#xD;
&#xD;
      Patients and methods: This study will be performed in 30 men with type 2 diabetes in a 2-step&#xD;
      protocol. We use a stable isotope method (D3-L-leucine) to study the kinetic of the&#xD;
      intestinal TRL-apoB48 and hepatic TRL-apoB100 (production and clearance rates).&#xD;
&#xD;
      In the first step of the protocol, all the patients will have a kinetic study of the&#xD;
      TRL-apoB48 in conditions of a saline infusion to measure the &quot;basal&quot; production and clearance&#xD;
      rates of the TRL-apoB48. In the second step, type 2 diabetic patients will be divided in 3&#xD;
      different paired groups: one performing an euglycaemic hyperinsulinic clamp to maintain&#xD;
      plasma glucose around 1g/l ; one performing an euglycaemic hyperinsulinic clamp to maintain&#xD;
      plasma glucose around 1g/l, but being infused with Endolipide 20 % (12,5 ml/h) and heparin&#xD;
      (250 U/h) to prevent the suppressive effect of insulin on plasma FFA ; one performing a&#xD;
      hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the&#xD;
      decreasing effect of insulin on plasma glucose.&#xD;
&#xD;
      The research ethics board of the Université de la Méditerranée (Comité de protection des&#xD;
      personnes-Sud méditerranée I) and the Afssaps (Agence française de sécurité sanitaire des&#xD;
      produits de santé) approved the study and all subjects gave written informed consent prior to&#xD;
      their participation.&#xD;
&#xD;
      General objective: Given the potential atherogenicity of the intestinal TRL-apoB48 particles,&#xD;
      understanding the factors and the biochemical mechanisms of their accumulation in the plasma&#xD;
      in the insulin resistant states may lead to specific therapeutic modalities that reduce their&#xD;
      plasma concentration and protect against the highly prevalent atherosclerosis that is&#xD;
      associated with insulin resistance and type 2 diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether an acute elevation of plasma insulin, secondarily to plasma insulin infusion, modulates the production and the clearance rates of intestinal TRL-apoB48 in type 2 diabetic patients in the fed state</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if this is a direct effect of insulin or an indirect effect due to the decrease of plasma FFA or the decrease of plasma glucose.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>euglycaemic hyperinsulinic clamp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the &quot;basal&quot; production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>euglycaemic hyperinsulinic clamp with Endolipide and heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the &quot;basal&quot; production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l but will be also infused with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hyperglycaemic hyperinsulinic clamp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the &quot;basal&quot; production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>saline infusion</intervention_name>
    <description>In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the &quot;basal&quot; production and clearance rates of the TRL-apoB48</description>
    <arm_group_label>euglycaemic hyperinsulinic clamp</arm_group_label>
    <arm_group_label>euglycaemic hyperinsulinic clamp with Endolipide and heparin</arm_group_label>
    <arm_group_label>hyperglycaemic hyperinsulinic clamp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>euglycaemic hyperinsulinic clamp</intervention_name>
    <description>an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l</description>
    <arm_group_label>euglycaemic hyperinsulinic clamp</arm_group_label>
    <arm_group_label>euglycaemic hyperinsulinic clamp with Endolipide and heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>infusion of Endolipide and heparin</intervention_name>
    <description>an infusion with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids</description>
    <arm_group_label>euglycaemic hyperinsulinic clamp with Endolipide and heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hyperglycaemic hyperinsulinic clamp</intervention_name>
    <description>a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose.</description>
    <arm_group_label>hyperglycaemic hyperinsulinic clamp</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  type 2 diabetic patients according to the criteria of the American Diabetes&#xD;
             Association&#xD;
&#xD;
          -  body mass index between 25 and 40 kg/m2&#xD;
&#xD;
          -  Subject the therapeutic care of which bases only on the oral anti-diabetics excepted&#xD;
             of glitazones and inhibitors of alpha-glucosidases&#xD;
&#xD;
          -  Subject without cardiovascular event in the previous 6 months or perturbing disease&#xD;
             the lipid balance assessment (dysthyroidism, pituitary disease, adrenal disease)&#xD;
&#xD;
          -  No anemia, no coagulation disturb, creatinine clearance &gt; 60 ml/min, fasting&#xD;
             triglycerides &lt; 4g/l&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to egg&#xD;
&#xD;
          -  Subject with severe disease associated with diabete&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rene Valero</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique-Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>July 30, 2009</study_first_submitted>
  <study_first_submitted_qc>July 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2009</study_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetic patients in the fed state</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

